Colon tumor removal showdown: which technique stops regrowth?
NCT ID NCT06815406
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two procedures—EMR and ESD—for removing large, flat colon growths (called LST-G) that can turn into cancer. About 282 adults will be randomly assigned to one of the two methods. The goal is to see which technique leads to fewer growths coming back within a year.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Azienda USL IRCCS di Reggio Emilia
RECRUITINGReggio Emilia, Italy
Contact Email: •••••@•••••
Contact
-
Ente Ospedaliero Ospedali Galliera
RECRUITINGGenova, Italy
Contact Email: •••••@•••••
Contact
-
IRCCS Azienda Ospedaliero Universitaria di Bologna - Sant'Orsola Malpighi
RECRUITINGBologna, Italy
Contact Email: •••••@•••••
Contact
-
Ospedale Civile di Baggiovara
RECRUITINGModena, Italy
Contact Email: •••••@•••••
Contact
-
Università Vita Salute - IRCCS
RECRUITINGMilan, Italy
Contact
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict who will survive a bowel surgery leak?
- Can a Two-Drug attack shrink Hard-to-Treat colorectal tumors?
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- A mobile app aims to turn health awareness into action — a trial puts it to the test
- Can a walking routine alter cancer biomarkers? new trial investigates
- Web tool aims to empower rare cancer patients in genomic choices